2014 Joint ACTRIMS-ECTRIMS Meeting

2014 Joint ACTRIMS-ECTRIMS Meeting | ECTRIMS 2014

The 2014 Joint ACTRIMS-ECTRIMS Meeting will feature "a premiere program covering a wide range of tracks and presentation topics including genetics, pathogenesis, factors that determine MS susceptibility and treatment strategies, to study outcomes and research advances, to the latest in regeneration and rehabilitation."

Conference Coverages

Dr. Wicks Comments on Technological Evolution in Data Collection
Dr. Wicks Comments on Technological Evolution in Data Collection
Paul Wicks, PhD, comments on physicians' acceptance of technological evolution in data collection at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
Dr. Wicks Discusses Internet-savvy Patients
Paul Wicks, PhD, discusses the surge in Internet-savvy patients at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
Dr. Nancy Discusses Cognitive Functionality and Progressive Multiple Sclerosis
Nancy Chiaravalloti, PhD, shares how cognitive function impacts patients with progressive multiple sclerosis at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
Dr. Mahad Discusses Protecting Nerve Cells in Progressive Multiple Sclerosis
Don Mahad, MD, PhD, discusses his research's focus of protecting nerve cells at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
Discussing the Efficacy of Alemtuzumab
Alasdair Coles, MD, University of Cambridge, shares his thoughts on the efficacy of alemtuzumab for patients with multiple sclerosis (MS) at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
New Analysis Shows Effectiveness, Cost-Effectiveness of Common MS Treatments
Assessment of long-term data on treatment utility demonstrates the effectiveness and cost-effectiveness of interferon-beta and glatiramer acetate for multiple sclerosis.
Sativex Spray Effectively Reduces Spasticity in Patients with MS
Treatment with Sativex oromucosal spray produces significant reductions in spasticity in patients with multiple sclerosis (MS) compared with placebo, but researchers reported no significant difference between the two in neurophysiologic measures.
Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials
Results from the RADIANCE study show that treatment with the selective S1P1 receptor modulator RPC1063 is associated with significant reductions in GD-enhancing lesions on MRI, as well as new or enlarging T2 lesions, compared with placebo.
Female Hormone Shows Promise for Reducing Disability in Some Patients with Multiple Sclerosis
Patients treated for two years with a combination of glatiramer acetate and estriol experienced a one-third reduction in relapse rate compared with patients who received glatiramer acetate and placebo.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$